Response;Respuesta

Revista Espanola de Cardiologia

Volumn 61, Issue 6, 2008, Pages 654-

  Zamora, Elisabet ^a   Lupón, Josep ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

BODY MASS; CARDIOVASCULAR RISK; DISEASE PREDISPOSITION; HEART FAILURE; HEART INFARCTION; HUMAN; LETTER; MORBIDITY; MORTALITY; OBESITY; PROGNOSIS;

EID: 46449104133     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1157/13123074     Document Type: Letter

References (5)

1. Rathore S, Curtis J, Wang Y, Bristol M, Krumholz H. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 2003;289:871-8.
2. Habbu A, Lakkis NM, Dokainish H. The obesity paradox: fact or fiction? Am J Cardiol. 2006;98:944-8.
3. Curtis JP, Selter JG, Wang Y, Rathore SS, Jovin IS, Jadbabaie F, et al. The obesity paradox: body mass index and outcomes in patients with heart failure. Arch Intern Med. 2005;165:55-61.
4. Cicoira M, Maggioni AP, Latini R, Barlera S, Carretta E, Janosi A, et al. Body mass index, prognosis and mode of death in chronic heart failure: Results from the Valsartan Heart Failure Trial. Eur J Heart Fail. 2007;9:397-402.
5. Kenchaiah S, Pocock SJ, Wang D, Finn PV, Zornoff LA, Skali H, et al; CHARM Investigators. Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation. 2007;116:627-36.